Published in Cancer Res on January 01, 2010
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
The in vitro spheroid melanoma cell culture assay: cues on tumor initiation? J Invest Dermatol (2010) 1.53
Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol (2010) 1.27
Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia (2011) 1.15
Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One (2010) 1.15
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest (2013) 1.12
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol (2011) 1.04
Isolation and molecular characterization of circulating melanoma cells. Cell Rep (2014) 1.02
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
From cancer stem cells to tumor maintenance in melanoma. J Invest Dermatol (2011) 1.01
BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res (2014) 0.99
Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell (2012) 0.97
Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des (2011) 0.93
Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget (2014) 0.92
Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther (2012) 0.89
Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin Dermatol (2013) 0.87
Gold nanoparticle-mediated detection of circulating cancer cells. Clin Lab Med (2012) 0.86
Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. J Cell Physiol (2013) 0.86
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget (2011) 0.85
Do cancer cells undergo phenotypic switching? The case for imperfect cancer stem cell markers. Sci Rep (2012) 0.85
Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype. PLoS One (2014) 0.84
Progress in understanding melanoma propagation. Mol Oncol (2010) 0.84
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res (2013) 0.82
Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol (2013) 0.82
Melanoma Cancer Stem Cells: Markers and Functions. Cancers (Basel) (2016) 0.80
Isolation of melanoma cell subpopulations using negative selection. Methods Mol Biol (2014) 0.79
Cancer Stem Cell Marker Phenotypes Are Reversible and Functionally Homogeneous in a Preclinical Model of Pancreatic Cancer. Cancer Res (2015) 0.79
Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chin J Cancer (2011) 0.79
The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn's hypothesis in the human melanoma system. Oncoimmunology (2012) 0.77
Association between tumorigenic potential and the fate of cancer cells in a syngeneic melanoma model. PLoS One (2013) 0.77
Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation. Apoptosis (2015) 0.76
Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin. Arch Biochem Biophys (2014) 0.75
NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. Cancer Immunol Res (2016) 0.75
Genetically engineered mouse models of melanoma. Cancer (2017) 0.75
Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations. BMC Cancer (2016) 0.75
Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J (1999) 10.82
Tumor growth need not be driven by rare cancer stem cells. Science (2007) 10.34
Identification of cells initiating human melanomas. Nature (2008) 8.28
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol (2004) 5.10
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A (2008) 4.60
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res (2008) 3.23
Development of a novel mouse glioma model using lentiviral vectors. Nat Med (2009) 3.08
Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res (2007) 3.00
Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin. J Cell Biol (2006) 2.32
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Looking ahead in cancer stem cell research. Nat Biotechnol (2009) 1.89
Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis (2006) 1.85
Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res (1991) 1.61
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30
Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res (2008) 1.19
Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A (2009) 1.17
Pigment production in murine melanoma cells is regulated by tyrosinase, tyrosinase-related protein 1 (TRP1), DOPAchrome tautomerase (TRP2), and a melanogenic inhibitor. J Invest Dermatol (1993) 0.95
Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res (2008) 0.85
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood (2005) 3.32
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A (2002) 3.19
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol (2002) 2.55
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov (2013) 2.08
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1.91
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis (2006) 1.85
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest (2004) 1.81
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci U S A (2013) 1.77
Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res (2006) 1.73
Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res (2002) 1.64
Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer (2006) 1.60
Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci U S A (2006) 1.58
Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res (2005) 1.58
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res (2005) 1.51
Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol (2005) 1.50
Memo mediates ErbB2-driven cell motility. Nat Cell Biol (2004) 1.47
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res (2008) 1.42
Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res (2011) 1.39
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol (2004) 1.35
Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem (2004) 1.31
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30
Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol (2004) 1.23
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene (2003) 1.21
Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res (2003) 1.21
The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci U S A (2004) 1.15
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A (2012) 1.15
B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res (2012) 1.15
p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.14
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood (2004) 1.13
Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development (2012) 1.13
Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol (2012) 1.12
Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes Chromosomes Cancer (2005) 1.12
Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents. Proc Natl Acad Sci U S A (2011) 1.12
Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest (2013) 1.12
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10
Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol (2009) 1.07
Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc Natl Acad Sci U S A (2007) 1.07
Colonic ganglioneuromatous polyposis and metastatic adenocarcinoma in the setting of Cowden syndrome: a case report and literature review. Hum Pathol (2011) 1.06
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene (2005) 1.05
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. Proc Natl Acad Sci U S A (2013) 1.04
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev (2012) 1.04
The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets (2005) 1.02
Utility of MMP-1, p53, E-cadherin, and collagen IV immunohistochemical stains in the differential diagnosis of adenomas with misplaced epithelium versus adenomas with invasive adenocarcinoma. Am J Surg Pathol (2002) 1.02
Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev (2014) 1.00
BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res (2014) 0.99
Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res (2013) 0.98
MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res (2012) 0.97
E-cadherin regulates the behavior and fate of epithelial stem cells and their progeny in the mouse incisor. Dev Biol (2012) 0.96
piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One (2011) 0.95
Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the Raf-->MEK-->ERK pathway. Exp Cell Res (2003) 0.93
Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. Mol Imaging Biol (2013) 0.90
Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. Cancer Res (2007) 0.90
Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol (2005) 0.90
Precancer in mice: animal models used to understand, prevent, and treat human precancers. Toxicol Pathol (2006) 0.88
ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. Biochem Biophys Res Commun (2005) 0.86
Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway. Cell Signal (2009) 0.86
Perifollicular fibroma in Birt-Hogg-Dubé syndrome: an association revisited. J Cutan Pathol (2012) 0.84
Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development (2004) 0.84
DeltaRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry. Mol Cell Biol (2003) 0.84
Investigative pathology: leading the post-genomic revolution. Lab Invest (2011) 0.83
Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol (2013) 0.82
Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. Hum Mol Genet (2013) 0.81
Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. Mol Cancer Res (2012) 0.80
Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model. Oncogene (2003) 0.80
Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle (2005) 0.80
A modular lentiviral and retroviral construction system to rapidly generate vectors for gene expression and gene knockdown in vitro and in vivo. PLoS One (2013) 0.80
RAF translocations expand cancer targets. Nat Med (2010) 0.79
Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res (2013) 0.79
A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin. Pigment Cell Melanoma Res (2008) 0.79
Meeting report: fourth international congress of the Society for Melanoma Research. Pigment Cell Melanoma Res (2008) 0.79
Familial multiple pilomatrixomas as a presentation of attenuated adenomatosis polyposis coli. J Cutan Pathol (2011) 0.79